Tailored hypoimmune nanovesicular delivery systems for cancer tumors
US12357704B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 6, 2020 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Oct 28, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicles (hypo-bioNVs) including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region or by a viral epitope recognition receptor (VERR). A method of making hypo-bioNVs. A method of treating an individual with cancer, by administering the hypo-bioNVs to an individual, targeting cancer cells, and treating the cancer. A method of targeting cells in an individual, by administering the hypo-bioNVs to an individual, and targeting cells to be destroyed or treated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.